Schafer, Eric S <br/><br/>
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).  [electronic resource] 

 -  Pediatric blood & cancer  08 2018 
 - e27066 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.27066  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Agents--administration & dosage<br/>Child<br/>Child, Preschool<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Furans--administration & dosage<br/>Humans<br/>Ketones--administration & dosage<br/>Male<br/>Maximum Tolerated Dose<br/>Microtubules--drug effects<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasms--drug therapy